🇺🇸 Nutropin AQ in United States

FDA authorised Nutropin AQ on 29 December 1995 · 3,181 US adverse-event reports

Marketing authorisation

FDA — authorised 29 December 1995

  • Application: BLA020522
  • Marketing authorisation holder: GENENTECH
  • Status: supplemented

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. No Adverse Event — 768 reports (24.14%)
  2. Headache — 439 reports (13.8%)
  3. Injection Site Pain — 419 reports (13.17%)
  4. Off Label Use — 265 reports (8.33%)
  5. Fatigue — 256 reports (8.05%)
  6. Arthralgia — 236 reports (7.42%)
  7. Pain — 229 reports (7.2%)
  8. Product Storage Error — 202 reports (6.35%)
  9. Product Dose Omission Issue — 186 reports (5.85%)
  10. Drug Dose Omission — 181 reports (5.69%)

Source database →

Other Endocrinology approved in United States

Frequently asked questions

Is Nutropin AQ approved in United States?

Yes. FDA authorised it on 29 December 1995.

Who is the marketing authorisation holder for Nutropin AQ in United States?

GENENTECH holds the US marketing authorisation.